![Richard Davis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Davis
Direttore/Membro del Consiglio presso NANEXA AB
Posizioni attive di Richard Davis
Società | Posizione | Inizio | Fine |
---|---|---|---|
NANEXA AB | Direttore/Membro del Consiglio | 01/01/2022 | - |
Independent Dir/Board Member | 01/01/2022 | - | |
Nouscom AG
![]() Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Direttore operativo | 23/05/2022 | - |
Corporate Officer/Principal | 01/09/2020 | 23/05/2022 |
Storia della carriera di Richard Davis
Precedenti posizioni note di Richard Davis
Società | Posizione | Inizio | Fine |
---|---|---|---|
Trino Therapeutics Ltd.
![]() Trino Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Trino Therapeutics Ltd. operates as a drug discovery and development company. It focuses on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease and other inflammatory indications. The company was founded by Neil Howard Frankish and Helen Sheridan in 1999 and is headquartered in Dublin, Ireland. | Direttore/Membro del Consiglio | 03/11/2014 | - |
Amministratore Delegato | 03/11/2014 | - | |
The Wellcome Trust Ltd.
![]() The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK. | Corporate Officer/Principal | - | - |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Direttore/Membro del Consiglio | - | - |
Formazione di Richard Davis
University of Leicester | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 4 |
Irlanda | 2 |
Svizzera | 2 |
Posizioni
Director/Board Member | 3 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Settori
Health Technology | 5 |
Consumer Services | 2 |
Miscellaneous | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
NANEXA AB | Health Technology |
Aziende private | 4 |
---|---|
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Trino Therapeutics Ltd.
![]() Trino Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Trino Therapeutics Ltd. operates as a drug discovery and development company. It focuses on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease and other inflammatory indications. The company was founded by Neil Howard Frankish and Helen Sheridan in 1999 and is headquartered in Dublin, Ireland. | Health Technology |
The Wellcome Trust Ltd.
![]() The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK. | Miscellaneous |
Nouscom AG
![]() Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Richard Davis
- Esperienza